147 related articles for article (PubMed ID: 15233659)
41. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
42. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
[TBL] [Abstract][Full Text] [Related]
43. [The proton pump especially steady in grip. Fast help for nightly reflux complaints].
MMW Fortschr Med; 2003 Dec; 145(51-52):39. PubMed ID: 14974330
[No Abstract] [Full Text] [Related]
44. Pantoprazole IV (Protonix IV).
Med Lett Drugs Ther; 2002 Apr; 44(1129):41-2. PubMed ID: 11981511
[No Abstract] [Full Text] [Related]
45. [When sour does not make merry at all . Fast relief for patients with reflux].
MMW Fortschr Med; 2003 Apr; 145(15):64. PubMed ID: 15104274
[No Abstract] [Full Text] [Related]
46. Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: a randomized controlled trial.
Svoboda P; Kantorová I; Ochmann J; Doubek J; Kozumplík L; Marsová J
Hepatogastroenterology; 1997; 44(15):886-90. PubMed ID: 9222709
[TBL] [Abstract][Full Text] [Related]
47. The novel use of an intravenous proton pump inhibitor in a patient with short bowel syndrome.
Tang SJ; Nieto JM; Jensen DM; Ohning GV; Pisegna JR
J Clin Gastroenterol; 2002 Jan; 34(1):62-3. PubMed ID: 11743248
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
Pisegna JR; Martin P; McKeand W; Ohning G; Walsh JH; Paul J
Am J Gastroenterol; 1999 Oct; 94(10):2874-80. PubMed ID: 10520836
[TBL] [Abstract][Full Text] [Related]
49. Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer.
van Rensburg CJ; Hartmann M; Thorpe A; Venter L; Theron I; Lühmann R; Wurst W
Am J Gastroenterol; 2003 Dec; 98(12):2635-41. PubMed ID: 14687809
[TBL] [Abstract][Full Text] [Related]
50. Intravenous proton pump inhibitors in the critical care setting.
Morgan D
Crit Care Med; 2002 Jun; 30(6 Suppl):S369-72. PubMed ID: 12072664
[TBL] [Abstract][Full Text] [Related]
51. [Cost-minimization study on the prescription of intravenous proton pump inhibitors: pantoprazole versus omeprazole].
García González F; Soler Company E; Hedo Aparicio G
Farm Hosp; 2003; 27(6):339-45. PubMed ID: 14974879
[TBL] [Abstract][Full Text] [Related]
52. Cost implications of administering intravenous proton pump inhibitors to all patients presenting to the emergency department with peptic ulcer bleeding.
Gagnon YM; Levy AR; Eloubeidi MA; Arguedas MR; Rioux KP; Enns RA
Value Health; 2003; 6(4):457-65. PubMed ID: 12859587
[TBL] [Abstract][Full Text] [Related]
53. [Validity of proton pump inhibitors' prescriptions in a department of internal medicine].
Marie I; Moutot A; Tharrasse A; Hellot MF; Robaday S; Hervé F; Lévesque H
Rev Med Interne; 2007 Feb; 28(2):86-93. PubMed ID: 17092611
[TBL] [Abstract][Full Text] [Related]
54. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice--a prospective study of the extent of the problem and predictive factors.
Craig DG; Thimappa R; Anand V; Sebastian S
QJM; 2010 May; 103(5):327-35. PubMed ID: 20211846
[TBL] [Abstract][Full Text] [Related]
55. Effect of a therapeutic maximum allowable cost (MAC) program on the cost and utilization of proton pump inhibitors in an employer-sponsored drug plan in Canada.
Mabasa VH; Ma J
J Manag Care Pharm; 2006 Jun; 12(5):371-6. PubMed ID: 16792443
[TBL] [Abstract][Full Text] [Related]
56. Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients.
Nasser SC; Nassif JG; Dimassi HI
World J Gastroenterol; 2010 Feb; 16(8):982-6. PubMed ID: 20180237
[TBL] [Abstract][Full Text] [Related]
57. Use of intravenous proton-pump inhibitors in a teaching hospital practice.
Hoover JG; Schumaker AL; Franklin KJ
Dig Dis Sci; 2009 Sep; 54(9):1947-52. PubMed ID: 19034652
[TBL] [Abstract][Full Text] [Related]
58. Intravenous pantoprazole utilization in a level 1 trauma center.
Edelman DA; Patel KR; Tyburski JG; Zimmerman LG
Surg Endosc; 2008 Apr; 22(4):967-73. PubMed ID: 17710489
[TBL] [Abstract][Full Text] [Related]
59. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.
Trifirò G; Corrao S; Alacqua M; Moretti S; Tari M; Caputi AP; Arcoraci V;
Br J Clin Pharmacol; 2006 Nov; 62(5):582-90. PubMed ID: 16822281
[TBL] [Abstract][Full Text] [Related]
60. The appropriateness of a proton pump inhibitor prescription.
Moran N; Jones E; O'Toole A; Murray F
Ir Med J; 2014; 107(10):326-7. PubMed ID: 25551900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
